Cargando…
Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes
The traditional oral pharmacological therapy for type 2 diabetes mellitus (T2DM) has been based on the prescription of metformin, a biguanide, as first line antihyperglycemic agent world over. It has been demonstrated that after 3 years of treatment, approximately 50 % of diabetic patients could ach...
Autores principales: | Fisman, Enrique Z., Tenenbaum, Alexander |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4587723/ https://www.ncbi.nlm.nih.gov/pubmed/26415691 http://dx.doi.org/10.1186/s12933-015-0294-0 |
Ejemplares similares
-
Gliptins: A New Class of Oral Antidiabetic Agents
por: Seshadri, K. G., et al.
Publicado: (2009) -
A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease
por: Fisman, Enrique Z, et al.
Publicado: (2009) -
Choosing a Gliptin
por: Gupta, Vishal, et al.
Publicado: (2011) -
Gliptins and Cardiovascular Outcomes: A Comparative and Critical Analysis after TECOS
por: Ghosal, Samit, et al.
Publicado: (2016) -
Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins
por: Filipova, Elena Pavlova, et al.
Publicado: (2015)